Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report)'s stock price fell 0.4% on Friday . The stock traded as low as $21.21 and last traded at $21.43. 494,245 shares were traded during trading, a decline of 88% from the average session volume of 3,963,933 shares. The stock had previously closed at $21.52.
Analyst Ratings Changes
A number of brokerages have commented on VKTX. B. Riley restated a "buy" rating and issued a $96.00 target price (down from $109.00) on shares of Viking Therapeutics in a research note on Friday, February 7th. Raymond James increased their price objective on Viking Therapeutics from $122.00 to $125.00 and gave the company a "strong-buy" rating in a report on Thursday, February 6th. Maxim Group dropped their price objective on shares of Viking Therapeutics from $120.00 to $70.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. HC Wainwright reissued a "buy" rating and set a $102.00 target price on shares of Viking Therapeutics in a research note on Wednesday, March 26th. Finally, Citigroup assumed coverage on Viking Therapeutics in a report on Friday, February 7th. They set a "neutral" rating and a $38.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Viking Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $89.75.
Read Our Latest Report on VKTX
Viking Therapeutics Stock Performance
The firm has a 50 day moving average price of $27.71 and a 200-day moving average price of $43.07. The company has a market cap of $2.50 billion, a P/E ratio of -22.22 and a beta of 0.84.
Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The biotechnology company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.05). During the same period last year, the business earned ($0.25) earnings per share. On average, sell-side analysts forecast that Viking Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.
Insider Activity at Viking Therapeutics
In other news, Director Sarah Kathryn Rouan acquired 1,240 shares of the firm's stock in a transaction on Monday, March 31st. The shares were purchased at an average cost of $24.15 per share, with a total value of $29,946.00. Following the acquisition, the director now directly owns 1,240 shares in the company, valued at $29,946. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 4.70% of the stock is owned by insiders.
Hedge Funds Weigh In On Viking Therapeutics
A number of institutional investors have recently added to or reduced their stakes in VKTX. FMR LLC grew its position in shares of Viking Therapeutics by 0.6% during the 4th quarter. FMR LLC now owns 16,715,438 shares of the biotechnology company's stock worth $672,629,000 after buying an additional 96,008 shares during the period. Geode Capital Management LLC increased its holdings in Viking Therapeutics by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 1,880,713 shares of the biotechnology company's stock worth $75,704,000 after acquiring an additional 17,046 shares during the last quarter. Braidwell LP raised its holdings in Viking Therapeutics by 27.9% during the 4th quarter. Braidwell LP now owns 1,479,666 shares of the biotechnology company's stock valued at $59,542,000 after acquiring an additional 322,689 shares during the period. Ameriprise Financial Inc. boosted its position in shares of Viking Therapeutics by 228.5% in the fourth quarter. Ameriprise Financial Inc. now owns 1,479,596 shares of the biotechnology company's stock valued at $59,540,000 after acquiring an additional 1,029,125 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its stake in Viking Therapeutics by 446.7% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,357,241 shares of the biotechnology company's stock valued at $54,615,000 after buying an additional 1,108,972 shares during the period. 76.03% of the stock is currently owned by institutional investors and hedge funds.
Viking Therapeutics Company Profile
(
Get Free Report)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Featured Articles
Before you consider Viking Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.
While Viking Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
